Search results
Results from the WOW.Com Content Network
0.8–1.5% (2019, using DSM-IV-TR and ICD-10) [ 2] Attention deficit hyperactivity disorder ( ADHD) is a neurodevelopmental disorder characterised by executive dysfunction occasioning symptoms of inattention, hyperactivity, impulsivity and emotional dysregulation that are excessive and pervasive, impairing in multiple contexts, and ...
Attention deficit hyperactivity disorder predominantly inattentive (ADHD-PI or ADHD-I), [3] is one of the three presentations of attention deficit hyperactivity disorder (ADHD). [4] In 1987–1994, there were no subtypes or presentations and thus it was not distinguished from hyperactive ADHD in the Diagnostic and Statistical Manual (DSM-III-R).
5.1% (hypothesized [ 1]) Cognitive disengagement syndrome ( CDS) is a syndrome characterized by developmentally-inappropriate, impairing and persistent levels of decoupled attentional processing from the ongoing external context and resultant hypoactivity. Symptoms often manifest in difficulties with staring, mind blanking, withdrawal, mental ...
t. e. The Vanderbilt ADHD Diagnostic Rating Scale ( VADRS) is a psychological assessment tool for attention deficit hyperactivity disorder (ADHD) symptoms and their effects on behavior and academic performance in children ages 6–12. This measure was developed by Mark L Wolraich at the Oklahoma Health Sciences Center [ 1] and includes items ...
Adult Attention Deficit Hyperactivity Disorder is the persistence of attention deficit hyperactivity disorder (ADHD) into adulthood. It is a neurodevelopmental disorder, meaning impairing symptoms must have been present in childhood, except for when ADHD occurs after traumatic brain injury. [ 1][ 2][ 3] Specifically, multiple symptoms must be ...
In 1980, the DSM-III introduced the term "ADD (Attention-Deficit Disorder) with or without hyperactivity." That terminology (ADD) technically expired with the revision in 1987 to ADHD in the DSM-III-R. In the DSM-IV, published in 1994, ADHD with sub-types was presented. The DSM-IV-TR was released in 2000, primarily to correct factual errors and ...
Atomoxetine. Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor medication used to treat attention deficit hyperactivity disorder (ADHD) [ 12] and, to a lesser extent, cognitive disengagement syndrome. [ 13][ 14][ 15] It may be used alone or along with psychostimulants. [ 16][ 17] It enhances the ...
ADHD was found more often in boys, at a rate of 2:1. [8] The most common form of ADHD was inattentive (2.95% of total population), followed by hyperactive/impulsive (2.77%), then combined (2.44%). [8] While differences in prevalence rate were found internationally, it is not clear whether this reflects true differences or changes in methodology ...